Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 125 for:    DMT
Previous Study | Return to List | Next Study

Effects of Dimethyltryptamine in Healthy Subjects (DMT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04353024
Recruitment Status : Not yet recruiting
First Posted : April 20, 2020
Last Update Posted : April 29, 2020
Sponsor:
Information provided by (Responsible Party):
University Hospital, Basel, Switzerland

Brief Summary:
N,N-dimethyltryptamine (DMT) is a naturally-occurring psychedelic substance widely used in recreational and spiritual settings. DMT can be used as a tool to induce an altered state of consciousness of interest in psychological and psychiatric research. DMT is rapidly metabolized by monoamine oxidase (MAO) A. Therefore, it is inactive when administered orally and has a very short duration of action when administered parenterally (<20 min).Therefore, an intravenous administration regime including a bolus and maintenance perfusion has been proposed to induce a stable and prolonged DMT experience allowing to study the psychological and autonomic acute effects of DMT. This administration allows to induce and end an altered state safely and quickly. The goal of the present study is to experimentally test different intravenous DMT administration schedules to investigate the subjective and autonomic effects of DMT in healthy subjects.

Condition or disease Intervention/treatment Phase
Healthy Drug: Dimethyltryptamine (DMT) Drug: Saline Phase 1

Detailed Description:
N,N-dimethyltryptamine (DMT) is a naturally-occurring psychedelic substance widely used in recreational and spiritual settings in the form of Ayahuasca. Similar to lysergic acid diethylamide (LSD) or psilocybin, DMT is considered a tool to induce an altered state of consciousness of interest in psychological and psychiatric research. Pharmacologically, DMT interacts with the serotonin 5-HT2A receptor similar to other classic hallucinogens including LSD and psilocybin. The main difference of DMT in comparison with LSD or psilocybin is inactivity when administered orally without monoamine oxidase (MAO) A inhibition and its short action when administered intravenously or by inhalation. In Ayahuasca, DMT is consumed iin combination with harmala alkaloids that inhibit MAO to increase the oral bioavailability of DMT and to prolong its action after oral use. Alternatively, an intravenous administration regime including a bolus and a one hour maintenance perfusion has been proposed to induce a stable and prolonged DMT experience, allowing to study the psychological and autonomic acute effects of DMT. Also, the maintenance perfusion administration allows to end an altered state of consciousness quickly. In the present study this model will be tested using four modified administration schemes. The goal of this study is to experimentally test different intravenous DMT administration schedules to investigate the subjective and autonomic effects of DMT in healthy subjects. The study is expected to inform researchers on dosing regimes of intravenous DMT as a tool to examine alterations of the mind and is of interest for psychology and psychiatry. This study does not intend to provide any therapeutic benefit for the participants. Currently, no study has validly determined the elimination half-life of DMT and other pharmacokinetic parameters. The key aim is to test the dose-response of DMT as well as the difference between the loading dose bolus and no-bolus perfusion conditions regarding pharmacokinetic, subjective, and autonomic effects including psychological and physical tolerability.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: Double-blind, placebo-controlled, 5-period cross-over design with 4 different doses of DMT and placebo
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Effects of Dimethyltryptamine (DMT) in Healthy Subjects: A Placebo-controlled Cross-over Study
Estimated Study Start Date : October 1, 2020
Estimated Primary Completion Date : October 1, 2021
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: Placebo
Bolus of 0 mg DMT + perfusion of 0 mg/min DMT over 60 min, resulting in a total dose of 0 mg DMT.
Drug: Saline
Intravenous saline bolus and/or saline maintenance perfusion over 90 min

Experimental: Low dose
Intravenous bolus of 0 mg DMT + perfusion of 0.6 mg/min DMT over 90 min, resulting in a total dose of 54 mg DMT.
Drug: Dimethyltryptamine (DMT)
Intravenous DMT bolus and/or DMT maintenance perfusion over 90 min

Drug: Saline
Intravenous saline bolus and/or saline maintenance perfusion over 90 min

Experimental: Low dose with bolus
Intravenous bolus of 15 mg DMT + perfusion of 0.6 mg/min DMT over 90 min, resulting in a total dose of 69 mg DMT.
Drug: Dimethyltryptamine (DMT)
Intravenous DMT bolus and/or DMT maintenance perfusion over 90 min

Experimental: High dose
Intravenous bolus of 0 mg DMT + perfusion of 1 mg/min DMT over 90 min, resulting in a total dose of 90 mg DMT.
Drug: Dimethyltryptamine (DMT)
Intravenous DMT bolus and/or DMT maintenance perfusion over 90 min

Drug: Saline
Intravenous saline bolus and/or saline maintenance perfusion over 90 min

Experimental: High dose with bolus
Intravenous bolus of 25 mg DMT + perfusion of 1 mg/min DMT over 90 min, resulting in a total dose of 115 mg DMT.
Drug: Dimethyltryptamine (DMT)
Intravenous DMT bolus and/or DMT maintenance perfusion over 90 min




Primary Outcome Measures :
  1. Altered states of consciousness profile [ Time Frame: 150 minutes ]
    Assessed once on each study day via 5 Dimensions of Altered States of Consciousness (5D-ASC) scale consisting of 94 items to be rated on a visual analog scale (0-100 mm), with higher values indicating stronger effects

  2. Subjective effect ratings over time [ Time Frame: 150 minutes ]
    Assessed 22 times on each study day via Subjective Effect Scale (SES), consisting of 4 questions to be rated on a Likert scale ranging from 1 to 10, with higher ratings indicating stronger effects


Secondary Outcome Measures :
  1. Subjective mood ratings [ Time Frame: 150 minutes ]
    Assessed twice on each study day via the Adjective Mood Rating Scale (AMRS) consisting of 60 items to be rated on a 4-point Likert scale, with higher ratings indicating stronger identification with the specific mood

  2. Mystical-type experiences [ Time Frame: 150 minutes ]
    Assessed once on each study day via States of Consciousness Questionnaire (SCQ) which measures the emergence and intensity of phenomenons occurring in altered states of consciousness on a 6-point Likert scale ranging from 0 ("not at all") to 5 ("extremely")

  3. Autonomic effects I [ Time Frame: 150 minutes ]
    Assessed 22 times on each study day via systolic and diastolic blood pressure, Emax

  4. Autonomic effects II [ Time Frame: 150 minutes ]
    Assessed 22 times on each study day via heart rate, Emax

  5. Plasma levels of DMT [ Time Frame: 150 minutes ]
    Assessed 21 times on each study day via blood samples

  6. Plasma levels of blood-derived neurotrophic factor (BDNF) [ Time Frame: 150 minutes ]
    Assessed 21 times on each study day via blood samples

  7. Plasma levels of oxytocin [ Time Frame: 60 minutes ]
    Assessed twice on each study day via blood samples

  8. Renal clearance of DMT [ Time Frame: 3 hours ]
    Collected once per study day via one-time interval urine recovery

  9. Effect moderation through personality traits I [ Time Frame: Baseline ]
    Assessed via NEO-Five-Factor-Inventory (NEO-FFI)

  10. Effect moderation through personality traits II [ Time Frame: Baseline ]
    Assessed via Freiburger Personality Inventory (FPI)

  11. Effect moderation through personality traits III [ Time Frame: Baseline ]
    Assessed via Saarbrücker Personality Questionnaire (SPF)

  12. Effect moderation through personality trait IV [ Time Frame: Baseline ]
    Assessed via Elliot Humility Scale (EHS) which measures the personality trait humility through 13 items on a 5-point Likert scale ranging from "strongly disagree" to "strongly agree"

  13. Effect moderation through personality trait V [ Time Frame: Baseline ]
    Assessed via Jankowski Humility Scale (JHS) which measures the personality trait humility through 18 items on a 5-point Likert scale ranging from "not at all" to "strongly"

  14. Effect moderation through personality trait VI [ Time Frame: Baseline ]
    Assessed via Arnett Inventory of Sensation Seeking (AISS-d)

  15. Effect moderation through personality trait VII [ Time Frame: Baseline ]
    Assessed via Defense Style Questionnaire (DSQ-40)

  16. Adverse effects [ Time Frame: 150 minutes ]
    Assessed via the List of Complaints (LC) which covers the emergence of 66 complaints in a yes/no format



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   25 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age between 25 and 65 years old
  • Sufficient understanding of the German language
  • Understanding of procedures and risks associated with the study
  • Willing to adhere to the protocol and signing of the consent form
  • Willing to refrain from the consumption of illicit psychoactive substances during the study
  • Abstaining from xanthine-based liquids from the evenings prior to the study sessions and during the sessions
  • Willing not to operate heavy machinery within 6 h of DMT administration
  • Willing to use double-barrier birth control throughout study participation
  • Body mass index between 18-29 kg/m2

Exclusion Criteria:

  • Chronic or acute medical condition
  • Current or previous major psychiatric disorder
  • Psychotic disorder or bipolar disorder in first-degree relatives
  • Hypertension (SBP>140/90 mmHg) or hypotension (SBP<85 mmHg)
  • Hallucinogenic substance use (not including cannabis) more than 20 times or any time within the previous two months
  • Pregnancy or current breastfeeding
  • Participation in another clinical trial (currently or within the last 30 days)
  • Use of medication that may interfere with the effects of the study medication
  • Tobacco smoking (>10 cigarettes/day)
  • Consumption of alcoholic beverages (>20 drinks/week)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04353024


Contacts
Layout table for location contacts
Contact: Matthias E Liechti, Prof. Dr. MD 061 328 68 68 ext +41 matthias.liechti@usb.ch
Contact: Laura Ley, MSc 061 328 77 42 ext +41 laura.ley@usb.ch

Sponsors and Collaborators
University Hospital, Basel, Switzerland
Investigators
Layout table for investigator information
Principal Investigator: Matthias E Liechti, Prof. Dr. MD University Hospital, Basel, Switzerland
Layout table for additonal information
Responsible Party: University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier: NCT04353024    
Other Study ID Numbers: BASEC 2020-00376
First Posted: April 20, 2020    Key Record Dates
Last Update Posted: April 29, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
N,N-Dimethyltryptamine
Hallucinogens
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Serotonin Receptor Agonists